Clinical Trials Logo

Non-hodgkin Lymphoma,B Cell clinical trials

View clinical trials related to Non-hodgkin Lymphoma,B Cell.

Filter by:

NCT ID: NCT03497533 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19

Trident19-H
Start date: August 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT03488251 Terminated - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Start date: August 20, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with gemcitabine and oxaliplatin (GEMOX) in participants with relapsed or refractory B-Cell NHL.

NCT ID: NCT02772198 Recruiting - Clinical trials for Non-Hodgkin Lymphoma, B-cell

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in children and young adults.

NCT ID: NCT02081937 Recruiting - Clinical trials for Mantle Cell Lymphoma

CART-19 Immunotherapy in Mantle Cell Lymphoma

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Patients receive anti-CD19-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells over a period of 4 or 5 consecutive days in an escalating dose. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 10 years.